← Back to Search

LY3200882 for Solid Cancers

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must have histological or cytological evidence of cancer
Must have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to disease progression or death (estimated at up to 12 months)
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe for people with solid tumors.

Who is the study for?
This trial is for people with solid tumors who can prove their cancer diagnosis, have good organ function, and are in decent physical shape (ECOG status of 0 or 1). They must be able to take pills. It's not for those with serious heart disease, other severe illnesses, or acute leukemia.Check my eligibility
What is being tested?
The study is testing the safety of a new drug called LY3200882 on solid tumors. Participants will also receive established cancer treatments like nab-Paclitaxel, radiotherapy, Cisplatin, LY3300054, and Gemcitabine.See study design
What are the potential side effects?
Possible side effects may include reactions at the infusion site from drugs like nab-Paclitaxel and Cisplatin; skin irritation from radiotherapy; and general effects such as fatigue or digestive issues from all treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer diagnosis was confirmed through lab tests on tissue or fluid samples.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to date of death from any cause (estimated at up to 12 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to date of death from any cause (estimated at up to 12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)
Secondary outcome measures
Duration of Response (DoR)
ORR: Percentage of Participants with CR or PR
Overall Survival (OS)
+3 more

Trial Design

8Treatment groups
Experimental Treatment
Group I: LY3200882 Schedule 2 ExpansionExperimental Treatment1 Intervention
Group II: LY3200882 Schedule 2 EscalationExperimental Treatment1 Intervention
Group III: LY3200882 Schedule 1 ExpansionExperimental Treatment1 Intervention
Group IV: LY3200882 Schedule 1 EscalationExperimental Treatment1 Intervention
Group V: LY3200882 + LY3300054Experimental Treatment2 Interventions
Group VI: LY3200882 + Gemcitabine + nab-PaclitaxelExperimental Treatment3 Interventions
Group VII: LY3200882 + Cisplatin + RadiationExperimental Treatment3 Interventions
Group VIII: Japanese Arm LY3200882Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intensity Modulated Radiotherapy
2016
N/A
~30
nab-Paclitaxel
2014
Completed Phase 3
~7680
Cisplatin
2013
Completed Phase 3
~1940
LY3200882
2019
Completed Phase 1
~30
LY3300054
2017
Completed Phase 1
~230
Gemcitabine
2017
Completed Phase 3
~2070

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,698 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,457 Total Patients Enrolled
~26 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top